Delving into the Latest Updates on Inclisiran sodium with Synapse

Overview

Basic Info

Drug Type

siRNA

Synonyms

ALN-PCSsc, Inclisiran, 因利司然

+ [10]

Target

PCSK9

Action

inhibitors

Mechanism

PCSK9 inhibitors(Proprotein convertase subtilisin kexin type 9 inhibitors), RNAi(RNA interference)

Therapeutic Areas

Cardiovascular DiseasesCongenital DisordersEndocrinology and Metabolic Disease+ [2]

Active Indication

Homozygous familial hypercholesterolemiaHypercholesterolemiaPrimary Hyperlipidemia+ [13]

Inactive Indication-

Originator Organization

Alnylam Pharmaceuticals, Inc.

Active Organization

Novartis Pharmaceuticals Corp.Corden Pharma SpASandoz GmbH

+ [7]

Inactive Organization

The Medicines Co.

Alcami Corp.

Alnylam Pharmaceuticals, Inc.

License Organization

National Health Service

The Medicines Co.

Alnylam Pharmaceuticals, Inc.

+ [5]

Drug Highest PhaseApproved

First Approval Date

European Union (09 Dec 2020),

Complex dyslipidemiaPrimary hypercholesterolemia

RegulationOrphan Drug (United States)

Login to view timeline

Structure/Sequence

Boost your research with our RNA technology data.

login

or

view full example data

Boost your research with our RNA technology data.

Sequence Code 31593325

Source: *****

Sequence Code 31594604

Source: *****

This study aims to evaluate the effectiveness and safety of implementing a systematic augmented low-density lipoprotein cholesterol (LDL-C) management care pathway initiated in hospitals for patients with Acute Coronary Syndrome. This pathway includes treatment with inclisiran on top of the standard of care (SOC), which consists of statins with or without ezetimibe, compared to a high-intensity SOC regimen alone (statins +/- ezetimibe).

Start Date30 Jun 2026

Sponsor / Collaborator

Novartis Pharmaceuticals Canada, Inc.

ChiCTR2600129275

/ RecruitingNot ApplicableIIT

A multi-arm, randomized, parallel, partially double-blind study conducted in healthy participants with elevated LDL-C and Lp(a) to evaluate the safety, tolerability, and efficacy of multiple doses of FB7023 injection.

Start Date09 Jun 2026

Sponsor / Collaborator

Zhejiang Xiaoshan Hospital

NCT07626281

/ RecruitingPhase 1

A Randomized, Open-label, Single-dose, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Inclisiran Containing Polysorbate 80 Versus Inclisiran Alone in Participants With Elevated Low-density Lipoprotein Cholesterol

The purpose of this study is to compare safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of the currently marketed formulation of inclisiran with a new formulation containing polysorbate 80 (PS80), after a single 284 mg subcutaneous (SC) administration.

Start Date09 Jun 2026

Sponsor / Collaborator

Novartis Pharmaceuticals Canada, Inc.

100 Clinical Results associated with Inclisiran sodium

Login to view more data

100 Translational Medicine associated with Inclisiran sodium

Login to view more data

100 Patents (Medical) associated with Inclisiran sodium

Login to view more data

308

Literatures (Medical) associated with Inclisiran sodium

01 Oct 2026·AMERICAN HEART JOURNAL

Design of VICTORION-2 Prevent: A randomized double-blind, placebo-controlled trial, assessing the impact of inclisiran on major adverse cardiovascular events in patients with established cardiovascular disease

Article

Author: Steg, Philippe Gabriel ; Menon, Venu ; Lesogor, Anastasia ; Bhatt, Deepak L ; Jukema, Johan Wouter ; Mena-Madrazo, Jorge ; Mehran, Roxana ; O'Donoghue, Fintan ; Liu, Karen ; Szarek, Michael ; Goodman, Shaun G ; Shao, Qing ; Martens, Pieter ; Stratz, Christian ; Zirlik, Andreas

RATIONALE:

Inclisiran is a small interfering ribonucleic acid targeting hepatic proprotein convertase subtilisin/kexin type 9 messenger RNA, that effectively reduces low-density lipoprotein cholesterol (LDL-C) levels. The effect of inclisiran on cardiovascular (CV) outcomes has not been formally tested.

METHODS:

VICTORION-2 Prevent (NCT05030428) is an ongoing, Phase 3 randomized, double-blind, placebo-controlled, international trial assessing the efficacy and safety of inclisiran in preventing CV events in patients with established atherosclerotic cardiovascular disease (ASCVD) receiving high-intensity statin therapy. Patients with established ASCVD (history of myocardial infarction [MI], ischemic stroke, or symptomatic peripheral artery disease), and fasting plasma LDL-C ≥ 1.8 mmol/L (70 mg/dL) despite high-intensity statin therapy (≥ 20 mg rosuvastatin or ≥ 40 mg atorvastatin daily) will be enrolled. Patients will be treated with inclisiran sodium 300 mg or placebo, administered subcutaneously at Day 1, Day 90, and every 6 months thereafter. The primary outcome will include time to first occurrence of 3-point major adverse CV events (3P-MACE; composite of CV death, MI, or ischemic stroke). Secondary outcomes will include time to occurrence of CV death, time to first occurrence of 4P-MACE (composite of 3P-MACE and urgent revascularization), and major adverse limb event (all adjudicated outcomes), time to occurrence of all-cause death, and long-term safety of inclisiran. Safety will be monitored using a selective safety data collection strategy.

CONCLUSION:

VICTORION-2 Prevent will provide robust data on CV benefits and safety of inclisiran in patients with established ASCVD and not at guideline-recommended LDL-C goals despite high-intensity statin treatment.

CLINICAL TRIAL REGISTRATION:

https://clinicaltrials.gov/study/NCT05030428.

01 Aug 2026·CARDIOVASCULAR DRUGS AND THERAPY

The 2025 ESC/EAS Dyslipidaemia Focused Update: Clinical Interpretation and Practical Implications

Review

Author: Bonanni, Luca ; Ferri, Nicola ; Cutolo, Ada

The 2025 ESC/EAS Dyslipidaemia Focused Update provides a targeted revision of the 2019 guidelines, integrating newly available evidence with the potential to influence clinical decision-making before the next full update. While LDL-C treatment targets remain unchanged, the document reshapes how they should be achieved, emphasizing faster therapeutic intensification, broader use of combination therapy and improved risk stratification with SCORE2/SCORE2-OP, lipoprotein(a) [Lp(a)] and coronary artery calcium (CAC) scoring. New evidence supporting bempedoic acid, inclisiran and evinacumab expands the therapeutic armamentarium, particularly for patients at high, very high and extreme cardiovascular risk or those with statin intolerance. In the acute coronary syndrome (ACS) setting, the update reinforces a more proactive, early-intensification approach. Overall, the Focused Update refines the operational framework of LDL-C management, promoting earlier, more personalized and more sustained lipid lowering to reduce cumulative atherosclerotic exposure.

01 Aug 2026·HEART

Ribonucleic acid and gene therapies in cardiovascular disease: clinical applications, delivery challenges and emerging precision tools

Review

Author: Andrew Baker ; Neil Craig ; David E Newby ; Marc Richard Dweck ; Neeraj Dhaun ; Craig Balmforth ; Alex J Jordan

Cardiovascular diseases remain a leading cause of global mortality despite advancements in pharmacotherapies, with current treatments facing challenges related to efficacy, tolerability and patient adherence. In response, advanced therapies, such as RNA and gene therapies, have emerged as a promising alternative for addressing both acquired and monogenic cardiovascular conditions. This review explores the current landscape of RNA and gene therapies for cardiovascular disease, focusing on RNA-based therapeutics such as small-interfering RNAs (siRNAs), antisense oligonucleotides and clustered regularly interspaced short palindromic repeats and associated Cas9 endonuclease (CRISPR-Cas9)-based gene editing systems. Recent European Medicines Agency and Food and Drug Administration-approved RNA therapies, including patisiran, vutrisiran and inclisiran, which employ lipid nanoparticle delivery systems, highlight the clinical potential of siRNAs for targeting hepatic molecular pathways. Emerging CRISPR-Cas9 technologies are poised to address genetic mutations at their source, offering permanent correction of pathogenic variants and the potential to treat a broad range of hereditary cardiovascular conditions. Together, these therapies represent a major leap forward in precision medicine, offering long-lasting therapeutic effects and improved patient care and adherence. However, many challenges remain, particularly in targeting such therapies to cardiac tissues and optimising delivery systems. This review discusses the current state of the art in cardiovascular RNA and gene therapies, including current evidence, delivery challenges and the current landscape of gene and RNA therapies in phase I clinical trials and beyond.

337

News (Medical) associated with Inclisiran sodium

20 Aug 2026

·www.biospace.com

Scribe’s early-stage IPO standout defies biotech’s derisking trend

iStock, jittawit.21 Scribe Therapeutics’ one-time epigenetic treatment is designed to slash the adherence burden of chronic cholesterol-lowering therapies while sidestepping the irreversibility of gene editing. Scribe Therapeutics is testing whether investors will embrace an earlier-stage bet in a market that favors derisked IPO stories. But Scribe’s outlier status goes far beyond the fact that the biotech filed to go public around the same time it was heading into the clinic. Less than a month since debuting and raising an upsized $150 million, Scribe—the only public company with an epigenetic silencer in the clinic—has seen its stock rise 43% from its first-day price of $21.50, resting at $31.05 by close on Wednesday. In comparison, biotech’s industry stock index, known as the XBI, has risen 12% over the last month. Beyond bucking the trend of late-stage biotechs with derisked assets debuting, the CRISPR-focused company is “a story that very quickly will be validated one way or the other, meaning they’re going to have a data update early next year,” Jack Bannister, senior managing director of equity capital markets at Leerink Partners, told BioSpace . Leerink served as one of the book-running managers for Scribe’s IPO. The biotech has designed a single dose of its main asset STX-1150 to lower LDL cholesterol (LDL-C), often known as “bad” cholesterol. The asset leverages epigenetic silencing, as opposed to gene editing, in hopes of significantly lowering the risk of atherosclerotic cardiovascular disease (ASCVD) without permanently changing the DNA sequence. STX-1150 targets PCSK9 and is currently entering Phase 1 trials in Australia, with interim results in patients with high LDL-C set to read out in the first half of next year. Beyond a clean safety profile, Leerink analysts hope STX-1150 can reduce LDL-C by 50% or more, which would translate to significantly improved adherence-adjusted efficacy compared to approved drugs such as Amgen’s Repatha, Novartis’ and Alnylam’s Leqvio or Merck’s newly approved Lipfendra , according to an Aug. 18 note. “We believe a positive readout [for Scribe] would drive a meaningful value inflection,” Leerink wrote. The analysts pointed to Eli Lilly’s $1 billion upfront acquisition of gene editor Verve Therapeutics last year, which came on the heels of Phase 1b safety and LDL-C lowering results among only 14 patients. “It’s the kind of dataset where investors should know quickly whether the drug’s working or not, and so it could be a material value inflection point right out of the gate,” Bannister said about Scribe, comparing the situation to the many biotechs that start with healthy volunteers or are just looking for safety signals early on. “That’s not Scribe. At Scribe, you should have a pretty good sense early and quickly whether it’s worth something or not.” Leerink believes STX-1150, which is delivered via lipid nanoparticle, could offer similar efficacy to current PCSK9-targeting injections or daily pills, while also improving convenience. The candidate is also designed to be safer than gene editors since no permanent genetic changes are made. Scribe also differs from other newly public biotechs in fundraise size. The valuation of the IPO is considerably lower, especially compared to record-breakers Kailera Therapeutics’ $625 million debut and Parabilis Medicines’ subsequent $670 million IPO . That’s by design, Bannister explained. “It was important for us to find a price that was attractive to not just existing investors but new investors as well,” he said, adding that they wanted to “price the deal to trade well.” The strategy seems to be paying off. While Scribe hasn’t been on the market as long as either Kailera or Parabilis, the biotech’s stock has risen more than the other two, with Kailera at a 31.4% loss from its first-day price and Parabilis up 24.5% as of Aug. 18, according to BioSpace ’s performance tracker . “Valuation matters. Companies who have leaned in too hard on value and tried to push at too high of a price haven’t traded as well this year,” Bannister said. “Those who have been much more conservative on price have traded well. It’s not a coincidence, right?” IPO Hair loss biotech Veradermics, up 656% since its IPO, credits the obesity boom After debuting on the public markets with $256.3 million and raking in an additional $472 million , Veradermics has emerged as one of biotech’s biggest post-IPO standouts. CEO Reid Waldman credits the weight loss craze for establishing consumer-driven channels. July 6, 2026 · 5 min read · Gabrielle Masson Read more Leerink believes Scribe will outperform market expectations, forecasting a $37 price target, according to the analyst note. The California-based biotech was co-created by four CRISPR pioneers, including CEO Benjamin Oakes and Nobel Prize winner Jennifer Doudna. Beyond main asset STX-1150, Scribe has also built a gene editing platform called X-Editor that underpins two potential pipeline candidates: STX-1200 for Lp(a) and STX-1400 for severe hypertriglyceridemia—the other two lipid drivers of ASCVD. This platform has already attracted deals from two major pharmas, Sanofi and Eli Lilly —something Leerink dubs “impressive external validation.” Both pharma companies invested in Scribe’s IPO as well. The biotech expects its cash runway to carry it into the first half of 2029.

IPOPhase 1AcquisitionGene Therapy

19 Aug 2026

·www.biospace.com

Novartis data at ESC Congress 2026 reinforce cardiovascular leadership and showcase progress in next-generation therapies

Late-breaking Phase IV VICTORION-CHALLENGE data will evaluate Leqvio ® (inclisiran) vs. bempedoic acid in achieving LDL-C goals New AZALEA-TIMI 71 analyses will further characterize the bleeding pro abelacimab in patients with atrial fibrillation, including recurrent bleeding events Lp(a)CCELERATE, in partnership with European Atherosclerosis Society (EAS), will explore strategies to help advance guideline-recommended Lp(a) testing in clinical practice Basel, August 19, 2026 – Novartis will present data from 10 abstracts across its cardiovascular portfolio at the 2026 European Society of Cardiology (ESC) Congress, reinforcing its leadership in addressing cardiovascular risk. “The data we are presenting at this year’s ESC Congress underscore our commitment to advancing cardiovascular science for patients who remain at risk despite current treatment,” said Ruchira Glaser, M.D., Global Head, Cardiovascular, Renal and Metabolic Development, Novartis. “From foundational medicines Leqvio and Entresto to promising investigational therapies, our portfolio reflects our focus on addressing persistent challenges in cardiovascular care.” Key abstracts accepted by ESC include: Medicine/Disease Abstract Title Presentation Details Leqvio ® Head-to-head comparison of inclisiran vs bempedoic acid for LDL C lowering in patients with high and very high cardiovascular risk: Results from the phase 4 VICTORION-CHALLENGE trial Tripoli (Hall B1) Late-Breaking Oral Presentation August 31, 08:15-08:30 CEST Leqvio ® An inclisiran-based treatment strategy reduces the need for therapy escalation to achieve low-density lipoprotein cholesterol goals: Exploratory findings from the VICTORION-Difference trial Exchange Circle 3 (Research Gateway – Hall A1) ePoster August 29, 09:15-10:00 CEST Abelacimab Effect of abelacimab vs. rivaroxaban on total bleeding events in patients with atrial fibrillation: an analysis from AZALEA-TIMI71 Science Box 2 (Research Gateway – Hall A1) Oral Presentation August 29, 09:30-10:30 CEST Lipoprotein (a) [Lp(a)] Mobilizing core and country-tailored implementation strategies to accelerate Lipoprotein(a) testing across Europe: findings from the Lp(a)CCELERATE contextual analysis Exchange Circle 6 (Research Gateway – Hall A1) ePoster August 29, 16:15-17:00 CEST Entresto ® Effects of sacubitril/valsartan versus enalapril on NT-proBNP and hs-troponin T in patients with heart failure due to Chagas disease: insights from the PARACHUTE-HF trial Station 5 (Research Gateway – Hall A1) ePoster August 31, 09:15-10:00 CEST Pacibekitug TRANQUILITY: Efficacy of monthly and quarterly dosing of pacibekitug (IL-6 ligand mAb) targeting inflammation in CKD with high cardiovascular risk Munich (Main Auditorium-Hall B3) Hot Line August 29, 08:45-09:00 CEST About Novartis in Cardiovascular Disease At Novartis, we're redefining cardiovascular care, shifting toward earlier action, expanding how we understand and treat cardiovascular disease, and pushing the boundaries of what's possible so more people can live longer, healthier lives. Building on our 40-year legacy, we're committed to shaping what's next in cardiovascular care through bold science and a diverse, industry-leading pipeline. Disclaimer This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. About Novartis Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 300 million people worldwide. Reimagine medicine with us: Visit us at and connect with us on LinkedIn , Facebook , X/Twitter and Instagram . # # # Novartis Media Relations E-mail: media.relations@novartis.com Novartis Investor Relations Central investor relations line: +41 61 324 7944 E-mail: investor.relations@novartis.com

AHAPhase 3Clinical Result

13 Aug 2026

·www.pharmamanufacturing.com

Aurisco site passes FDA inspection for generic oligonucleotide manufacturing

Aurisco Pharmaceutical, a China-based oligonucleotide and peptide manufacturer, said its Yangzhou site has successfully completed a U.S. Food and Drug Administration (FDA) preapproval inspection, which the company claims is the first FDA inspection of a generic oligonucleotide API manufacturer. The five-day inspection, conducted June 15-19, covered current Good Manufacturing Practice (cGMP) compliance for oligonucleotides, GLP-1 peptides including semaglutide and tirzepatide, as well as small molecule manufacturing. The inspection was related to inclisiran sodium. According to Aurisco , the FDA’s Establishment Inspection Report (EIR) confirmed that the company had addressed the inspector’s observations through an approved corrective and preventive action (CAPA) plan. The inspector also reviewed the site’s GMP systems, documentation, inspection organization, and personnel expertise. Aurisco said the inspection could support future development of generic oligonucleotide APIs, including inclisiran, vutrisiran, nusinersen, and eplontersen. The Yangzhou site previously underwent an FDA inspection in 2023 and provides both contract development and manufacturing organization (CDMO) services and generic API manufacturing.

OligonucleotideClinical Study

100 Deals associated with Inclisiran sodium

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	Inclisiran sodium	C10AX	DB14901

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Homozygous familial hypercholesterolemia	United States	Novartis Pharmaceuticals Corp.	12 Feb 2026
Hypercholesterolemia	Japan	Novartis Pharma KK	25 Sep 2023
Primary Hyperlipidemia	United States	Novartis Pharmaceuticals Corp.	07 Jul 2023
Atherosclerosis	Australia	Novartis Pharmaceuticals Australia Pty Ltd.	14 Sep 2021
Heterozygous familial hypercholesterolemia	Canada	Novartis Pharmaceuticals Canada, Inc.	26 Jul 2021
Hypercholesterolemia, Familial	Canada	Novartis Pharmaceuticals Canada, Inc.	26 Jul 2021
Complex dyslipidemia	European Union	Novartis Europharm Ltd.	09 Dec 2020
Complex dyslipidemia	Iceland	Novartis Europharm Ltd.	09 Dec 2020
Complex dyslipidemia	Liechtenstein	Novartis Europharm Ltd.	09 Dec 2020
Complex dyslipidemia	Norway	Novartis Europharm Ltd.	09 Dec 2020
Primary hypercholesterolemia	European Union	Novartis Europharm Ltd.	09 Dec 2020
Primary hypercholesterolemia	Iceland	Novartis Europharm Ltd.	09 Dec 2020
Primary hypercholesterolemia	Liechtenstein	Novartis Europharm Ltd.	09 Dec 2020
Primary hypercholesterolemia	Norway	Novartis Europharm Ltd.	09 Dec 2020

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute Coronary Syndrome	Phase 3	China	Novartis Pharmaceuticals Canada, Inc.	03 Oct 2025
Acute Coronary Syndrome	Phase 3	Japan	Novartis Pharma AG	03 Oct 2025
Acute Coronary Syndrome	Phase 3	Japan	Novartis Pharmaceuticals Canada, Inc.	03 Oct 2025
Acute Coronary Syndrome	Phase 3	Japan	Novartis Pharmaceutical Manufacturing GmbH	03 Oct 2025
Acute Coronary Syndrome	Phase 3	Japan	Corden Pharma SpA	03 Oct 2025
Acute Coronary Syndrome	Phase 3	Argentina	Novartis Pharma AG	03 Oct 2025
Acute Coronary Syndrome	Phase 3	Argentina	Corden Pharma SpA	03 Oct 2025
Acute Coronary Syndrome	Phase 3	Argentina	Novartis Pharmaceuticals Canada, Inc.	03 Oct 2025
Acute Coronary Syndrome	Phase 3	Argentina	Novartis Pharmaceutical Manufacturing GmbH	03 Oct 2025
Acute Coronary Syndrome	Phase 3	Australia	Novartis Pharmaceuticals Canada, Inc.	03 Oct 2025

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05192941 (VICTORION-Difference \| V-DIFFERENCE, CTgov)	Phase 4	Heterozygous familial hypercholesterolemia \| Hypercholesterolemia	1,770	Inclisiran Sodium (Inclisiran)	avzqzdhvqz = bdqkoqpmng ngkqqgpyyq (ffpdfzwhsu, parhrolinw - ehvxxfntln) View more	-	14 Apr 2026
				Placebo (Placebo)	avzqzdhvqz = ptamzbntap ngkqqgpyyq (ffpdfzwhsu, ajpgcpflrf - efxptmfsyp) View more
NCT05192941 (VICTORION-Difference \| V-DIFFERENCE, NEWS) Manual	Phase 4	Hypercholesterolemia	1,770	Inclisiran sodium 300 mg	kxuxlwcqnn(yaapainmrs) = hbqvcrwcai bqgtnzdprr (xjhiqxqhex ) Met View more	Positive	30 Aug 2025
				Placebo	kxuxlwcqnn(yaapainmrs) = xqqhormzun bqgtnzdprr (xjhiqxqhex ) Met View more
NCT05763875 (V-MONO \| VICTORION-Mono, CTgov)	Phase 3	Primary hypercholesterolemia	350	Matching Placebo for Ezetimibe+Inclisiran (Inclisiran)	icexofzxwz(kkkkltbnfk) = mghtskwhmb xbhdcndwng (ffmmmkmxfw, tipywzfffu - dqcpkmglvn) View more	-	13 Aug 2025
				Matching Placebo for Inclisiran+Ezetimibe (Ezetimibe)	icexofzxwz(kkkkltbnfk) = eikzqmnjzt xbhdcndwng (ffmmmkmxfw, cyvhinbgxs - kbcevrssad) View more
NCT05763875 (VICTORION-Mono, Pubmed) Manual	Phase 3	Hypercholesterolemia	350	Inclisiran	gbwnzidgmo(bgobgrcrer) = glhrlndddc cwqtclvutr (gynldkjtdx )	Positive	01 Jul 2025
				Ezetimibe	gbwnzidgmo(bgobgrcrer) = jpfdhnegso cwqtclvutr (gynldkjtdx )
NCT04652726 (ORION-16, CTgov)	Phase 3	Heterozygous familial hypercholesterolemia	141	Inclisiran sodium (Part 1- Inclisiran)	dxrqfcstgb(skjufjizgx) = nbmnqwfvnq fjtsacethr (cgeemltfgg, xjgyifqymc - wvtpnzedcb) View more	-	10 Jun 2025
				Placebo (Part 1 - Placebo)	dxrqfcstgb(skjufjizgx) = pvuwpppxvg fjtsacethr (cgeemltfgg, vbbmtrajbo - elxjpzvdkk) View more
NCT04659863 (ORION-13, CTgov)	Phase 3	Homozygous familial hypercholesterolemia	13	Placebo (Part 1 - Placebo)	vsbxqpktdn(leuxmubjgi) = xasfqyekea bwezxbrwfl (ltyevxkvvc, 30.52) View more	-	31 May 2025
				Inclisiran (Part 2 - Inclisiran (Total))	bebkuiuqvz(plymhibuzf) = uhrguprcba nqhovytbjs (sdqbfgmnva, 25.28) View more
NCT05888103 (V-Mono China, CTgov)	Phase 3	Dyslipidemias \| Primary hypercholesterolemia	207	Matching Placebo for Inclisiran+Inclisiran (Inclisiran - Inclisiran)	jnmztyoleh(amoimnlmvc) = fkvgixnzwl qtydshvlvg (unjbqpsngr, jpoazlwbmo - hyqvouovmn) View more	-	20 Apr 2025
				Matching Placebo for Inclisiran+Inclisiran (Placebo- Inclisiran)	jnmztyoleh(amoimnlmvc) = krrguympcv qtydshvlvg (unjbqpsngr, hahchjqsko - oyrfdlqxmd) View more
ORION-18 (NEWS) Manual	Phase 3	Atherosclerosis	232	英克司兰钠 300 mg	rermnmgqaw(uxftdvolhf) = icpxcuyleg kzyubafzug (stnwoiyrga ) View more	Positive	06 Mar 2025
				安慰剂	rermnmgqaw(uxftdvolhf) = leabmnhvnb kzyubafzug (stnwoiyrga )
NCT03814187 (ORION-8, Pubmed \| Cardiovasc Res)	Phase 2/3	Hyper LDL cholesterolaemia \| Homozygous familial hypercholesterolemia \| Heterozygous familial hypercholesterolemia	3,274	Inclisiran	xasquycayx(rjwpohrjvm) = 5.9% of inclisiran-treated patients wuttzknecy (ftkwvkrxtn )	Positive	14 Oct 2024
ESC2024	Not Applicable	-	-	Inclisiran	bowhcsdtkl(vdqcbkixht) = rjbngayppa bllentcmbl (acfchdmdni ) View more	-	31 Aug 2024